Tienilic acid-induced autoimmune hepatitis: Anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9

Molecular Pharmacology

Volumn 50, Issue 2, 1996, Pages 326-333

  Lecoeur, S ^b   Andre C ^b   Beaune, P H ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOCHROME P450; TIENILIC ACID;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGENICITY; ARTICLE; AUTOIMMUNE HEPATITIS; CONFORMATIONAL TRANSITION; DRUG METABOLISM; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; KIDNEY MICROSOME; LIVER MICROSOME; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; EPITOPE MAPPING; HEPATITIS, TOXIC; HUMANS; INFANT; RABBITS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TICRYNAFEN;

EID: 0029790276     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Beaune, P. H., P. M. Dansette, D. Mansuy, L. Kiffel, M. Finck, C. Amar, J. P. Leroux, and J. C. Homberg. Human antiendoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome that hydroxylates the drug. Proc. Natl. Acad. Sci. USA 84:551-555 (1987).
2. Bourdi, M., D. Larrey, J. Nataf, J. Bernuau, D. Pessayre, M. Iwasaki, F. P. Guengerich, and P. H. Beaune. Antiliver endoplasmic reticulum autoantibodies are directed against human cytochrome P450 1A2: a specific marker for dihydralazine-induced hepatitis. J. Clin. Invest. 85:1967-1973 (1990).
3. Leeder, J. S., R. J. Riley, V. A. Cook, and S. P. Spielberg. Human anticytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J. Pharmacol. Exp. Ther. 263:360-367 (1992).
4. Manns, M., E. F. Johnson, I. C. J. Griffin, E. M. Tan, and K. F. Sullivan. The major target of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 db1. J. Clin. Invest. 83:1066-1072 (1989).
5. Manns, M. P., K. J. Griffin, L. C. Quattrochi, M. Sacher, H. Thaler, R. H. Tukey, and E. F. Johnson. Identification of cytochrome P4501A2 as a human autoantigen. Arch. Biochem. Biophys. 280:229-232 (1990).
6. Bednarek, J., J. Furmaniak, N. Wedlock, Y. Kiso, A. Baumann-Antczak, S. Fowler, H. Krishnan, J. A. Craft, and B. Rees Smith. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison's disease. FEBS Lett. 309:51-55 (1992).
7. Baumann-Antczak, A., N. Wedlock, J. Bednarek, Y. Kiso, H. Krishnan, S. Fowler, B. Rees Smith, and J. Furmaniak. Autoimmune Addison's disease and 21-hydroxylase. Lancet 340:429-430 (1992).
8. Krohn, K, R. Uibo, E. Aavik, P. Peterson, and K. Savilahti. Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17a-hydroxylase. Lancet 339:770-773 (1992).
9. Winqvist, O., J. Gustafsson, F. Rorsman, F. A. Karlsson, and O. Kämpe. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. J. Clin. Invest. 92:2377-2385 (1993).
10. Uibo, R., E. Aavik, P. Peterson, J. Perheentupa, S. Aranko, R. Pelkonen, and K. J. E. Krohn. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J. Clin. Endocrinol. Metab. 78:323-328 (1994).
11. Lecoeur, S., E. Bonierbale, D. Challine, J. C. Gautier, P. Valadon, P. M. Dansette, R. Catinot, F. Ballet, D. Mansuy, and P. H. Beaune. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem. Res. Toxicol. 7:434-442 (1994).
12. Lopez Garcia, M. P., P. M. Dansette, P. Valadon, C. Amar, P. H. Beaune, F. P. Guengerich, and D. Mansuy. Human liver P450 expressed in yeast as tools for reactive metabolite formation studies: oxidative activation of tienilic acid by P450 2C9 and 2C10. Eur. J. Biochem. 213:223-232 (1993).
13. Manns, M. P., K. J. Griffin, K. F. Sullivan, and E. F. Johnson. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J. Clin. Invest. 88:1370-1378 (1991).
14. Yamamoto, A. M., D. Cresteil, O. Boniface, F. F. Clerc, and F. Alvarez. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur. J. Immunol. 23:1105-1111 (1993).
15. Peterson P., and K. J. E. Krohn. Mapping of B cell epitopes on steroid 17 a-hydroxylase, an autoantigen in autoimmune polyglandular syndrome type I. Clin. Exp. Immunol. 98:104-109 (1994).
16. Wedlock, N., T. Asawa, A. Baumann-Antczak, B. Rees Smith, and J. Furmaniak. Autoimmune Addison's disease: analysis of autoantibody binding sites on human steroid 21-hydroxylase. FEBS Lett. 332:123-126 (1993).
17. Song, Y. H., E. L. Connor, A. Muir, J. X. She, B. Zorovich, D. Derovanesian, and N. MacLaren. Autoantibody epitope mapping of the 21-hydroxylase antigen in autoimmune Addison's disease. J. Clin. Endocrinol. Metab. 78:1108-1112 (1994).
18. Leeder, J. S., A. Gaedigk, X. Lu, and V. A. Cook. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol. Pharmacol. 49: 234-243 (1996).
19. Leeder, J. S., A. Gaedigk, and X. Lu. Epitope mapping studies of human anti-CYP3A antibodies in a patient with anticonvulsant hypersensitivity, in Proceedings of the Sixth North American ISSX Meeting, ISSX, Bethesda, MD, 53 (1994).
20. Homberg, J. C., C. Andre, and N. Abuaf. A new anti-liver kidney microsome antibody (anti-LKM2) in tienilic acid induced hepatitis. Clin. Exp. Immunol. 55:561-570 (1984).
21. Kimura, S., J. Pastewka, H. V. Gelboin, and F. J. Gonzalez. cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res. 15:10053-10054 (1987).
22. Studier, F. W., and B. Moffat. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189: 113-130 (1986).
23. Belloc, C., S. Baird, J. Cosme, S. Lecoeur, J. C. Gautier, D. Challine, I. de Waziers, J. P. Flinois, and P. H. Beaune. Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology 106:207-219 (1996).
24. Smith, D. B., and K. S. Johnson. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione-S-transferase. Gene 67:31-40 (1988).
25. Nelson, D. R., L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Nebert. P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 6:1-42 (1996).
26. Sanger, F., A. R. Coulson, G. F. Hong, D. F. Hill, and G. B. Peterson. J. Mol. Biol. 162:729-773 (1982).
27. Laemmli, U. K. Cleavage of structural properties during the assembly of the head of bacteriophage T4. Nature (Lond.) 227:680-685 (1970).
28. Towbin, H., T. Staehelin, and J. Gordon. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Nail. Acad. Sci. USA 76:4350-4354 (1979).
29. Stott, D. I. Immunoblotting and dot blotting. J. Immunol. Methods 119: 153-187 (1989).
30. Birk, H. W., and H. Koepsell. Reaction of monoclonal antibodies with plasma membrane proteins after binding on nitro cellulose: renaturation of antigenic sites and reduction of nonspecific antibody binding. Anal. Biochem. 164:12-22 (1987).
31. Blundell, T. L., B. L. Sibanda, M. J. E. Sternberg, and J. M. Thornton. Knowledge-based prediction of protein structures and the design of novel molecules. Nature (Lond.) 326:347-352 (1987).
32. Duclos-Vallee, J. C., O. Hajoui, A. M. Yamamoto, E. Jacqz-Aigrain, and F. Alvarez. Conformational epitopes on CYP2D6 are recognized by liver/ kidney microsomal antibodies. Gastroenterology 108:470-476 (1995).
33. Finke, R., P. Seto, and B. Rapoport. Evidence for the highly conformational nature of the epitope(s) on human thyroid peroxidase that are recognized by sera from patients with Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab. 71:53-59 (1990).
34. Richter, W., Y. Shi, and S. Baekkeskov. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc. Natl. Acad. Sci. USA 90:2832-2836 (1993).
35. Leung, P. S. C., D. T. Chuang, R. M. Wynn, S. Cha, D. J. Danner, A. Ansari, R. L. Coppel, and M. E. Gershwin. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology 22:505-513 (1995).
36. Korzekwa, K. R., and J. P. Jones. Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics 3:1-18 (1993).
37. Hasemann, C. A., R. G. Kurumbail, S. S. Boddupalli, J. A. Peterson, and J. Deisenhofer. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 2:41-62 (1995).
38. Poulos, T. L. Modeling of mammalian P450s on the basis of P450cam X-ray structure. Methods Enzymol. 206:11-30 (1991).
39. Beaune, P., D. Pessayre, P. Dansette, D. Mansuy, and M. Manns. Autoantibodies against cytochromes P-450: role in human diseases. Adv. Pharmacol. 30:199-245 (1994).
40. Bourdi, M., M. Tinel, P. H. Beaune, and D. Pessayre. Interactions of dihydralazine with cytochromes P450 1A: a possible explanation for the appearance of anti-cytochrome P450 1A2 autoantibodies. Mol. Pharmacol. 45:1287-1295 (1994).